Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Osteoporosis tied to mortality risk in women with multiple myeloma

Rosko AE et al. Clin Lymphoma Myeloma Leuk. 2018 Sep;18(9):597-602.e1.

Key clinical point: Preexisting osteoporosis is an important risk factor for death in postmenopausal women who develop multiple myeloma.

Major finding: Risk of death was elevated in women at high risk of fracture (covariate-adjusted hazard ratio, 1.51; 95% confidence interval, 1.01-2.25; P = .044) versus women with low fracture risk.

Study details: Retrospective analysis of the Women’s Health Initiative data set including 362 postmenopausal women who were cancer free at baseline and developed myeloma over the course of study follow-up.

Disclosures: The analysis was supported in part by the National Cancer Institute. The researchers reported having no relevant financial disclosures.

Read the article.


Rosko AE et al. Clin Lymphoma Myeloma Leuk. 2018 Sep;18(9):597-602.e1.

This Week's Must Reads

Immune system changes play a role in AML relapse, Christopher MJ et al. N Engl J Med. 2018 Oct 31. doi: 10.1056/NEJMoa1808777.

Haploidentical allo-HCT possible even in relapsed myeloma, Sahebi F, et al. Biol Blood Marrow Transplant. 2018 Sep 20. pii: S1083-8791(18)30575-5.

Venetoclax plus HMA studied in AML, DiNardo C et al. Blood. 2018 Oct 25. doi: 10.1182/blood-2018-08-868752.

The role of PTPN22 R620W in CLL, Leukemia & Lymphoma 2018